James E. Hoffman

2.5k total citations
68 papers, 579 citations indexed

About

James E. Hoffman is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, James E. Hoffman has authored 68 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hematology, 33 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in James E. Hoffman's work include Multiple Myeloma Research and Treatments (33 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (22 papers) and Chronic Lymphocytic Leukemia Research (11 papers). James E. Hoffman is often cited by papers focused on Multiple Myeloma Research and Treatments (33 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (22 papers) and Chronic Lymphocytic Leukemia Research (11 papers). James E. Hoffman collaborates with scholars based in United States, Belgium and United Kingdom. James E. Hoffman's co-authors include Raymond L. Comenzo, Richard M. Steingart, Heather Landau, Hani Hassoun, Beryl Z. Greenberg, Robert J. Tanenberg, Frederick C. Goetz, Jennifer Liu, Adam D. Cohen and Joanne Chou and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

James E. Hoffman

60 papers receiving 554 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James E. Hoffman United States	13	318	216	200	126	95	68	579
Simona Casarini Italy	13	609 1.9×	124 0.6×	157 0.8×	157 1.2×	62 0.7×	15	679
Gregory P. Kaufman United States	10	377 1.2×	177 0.8×	230 1.1×	141 1.1×	20 0.2×	26	520
Jack Khouri United States	13	250 0.8×	265 1.2×	272 1.4×	74 0.6×	33 0.3×	93	511
Kate L. Lowe United Kingdom	12	132 0.4×	212 1.0×	314 1.6×	40 0.3×	28 0.3×	14	589
Eva Medvedova United States	10	536 1.7×	567 2.6×	373 1.9×	120 1.0×	68 0.7×	47	737
David Lavergne France	9	514 1.6×	83 0.4×	138 0.7×	117 0.9×	25 0.3×	18	581
George Tsirakis Greece	17	229 0.7×	386 1.8×	274 1.4×	85 0.7×	26 0.3×	43	628
Wim M.J. Vuist Netherlands	11	170 0.5×	278 1.3×	66 0.3×	62 0.5×	107 1.1×	16	635
Hugh J. B. Goodman United Kingdom	12	666 2.1×	139 0.6×	172 0.9×	183 1.5×	8 0.1×	22	758
Shou Ching Tang Canada	6	100 0.3×	177 0.8×	200 1.0×	65 0.5×	60 0.6×	7	506

Countries citing papers authored by James E. Hoffman

Since Specialization

Citations

This map shows the geographic impact of James E. Hoffman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Hoffman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Hoffman more than expected).

Fields of papers citing papers by James E. Hoffman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Hoffman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Hoffman. The network helps show where James E. Hoffman may publish in the future.

Co-authorship network of co-authors of James E. Hoffman

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Hoffman. A scholar is included among the top collaborators of James E. Hoffman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Hoffman. James E. Hoffman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoffman, James E., Naresh Bumma, Joshua Richter, et al.. (2025). Patient-Reported Quality of Life with Linvoseltamab in Triple-Class Exposed Patients with Relapsed/Refractory Multiple Myeloma: 2-year Results from the LINKER-MM1 Phase 1/2 Clinical Trial. Clinical Lymphoma Myeloma & Leukemia. 25. S116–S116. 1 indexed citations

Kowalski, Andrew S., Benjamin Diamond, David G. Coffey, et al.. (2025). Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. Blood Advances. 9(19). 4979–4986.

Thoren, Katie, Dan Qu, James E. Hoffman, et al.. (2024). Enhanced Detection of M-Protein in Non-Secretory and Oligo-Secretory Multiple Myeloma Using MALDI-TOF Mass Spectrometry. Blood. 144(Supplement 1). 6847–6847.

Kowalski, Andrew S., David G. Coffey, Benjamin Diamond, et al.. (2024). Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma. Blood. 144(Supplement 1). 2389–2389.

Gallo, Ryan A., et al.. (2023). Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure. The American Journal of Cardiology. 204. 360–365. 9 indexed citations

Hoffman, James E., et al.. (2023). Ocular surface changes associated with belantamab mafodotin treatment. Graefe s Archive for Clinical and Experimental Ophthalmology. 261(11). 3201–3204.

Lee, Hans C., Naresh Bumma, Joshua Richter, et al.. (2023). LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 41(16_suppl). 8006–8006. 37 indexed citations

Zonder, Jeffrey A., Joshua Richter, Naresh Bumma, et al.. (2021). Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 138(Supplement 1). 160–160. 27 indexed citations

Totiger, Tulasigeri M., Terrence Bradley, Francesco Maura, et al.. (2021). Combination Venetoclax and Selinexor Effective in Relapsed/Refractory Multiple Myeloma with Translocation t(11;14). Blood. 138(Supplement 1). 2270–2270. 2 indexed citations

10.

Chaulagain, Chakra P., et al.. (2020). Liver failure due to relapsed myeloma and hepatic iron overload. ecancermedicalscience. 14. 1028–1028. 2 indexed citations

11.

Hoffman, James E., Naomi Dempsey, & Vaishali Sanchorawala. (2020). Systemic Amyloidosis Caused by Monoclonal Immunoglobulins. Hematology/Oncology Clinics of North America. 34(6). 1099–1113. 9 indexed citations

12.

Saini, Vasu, et al.. (2020). Paraneoplastic Cerebellar Degeneration in Diffuse Large B-cell Lymphoma and Review of Associated Onconeural Antibodies. Clinical Lymphoma Myeloma & Leukemia. 20(6). e336–e340. 1 indexed citations

13.

Rapoport, Aaron P., James E. Hoffman, Jonathan L. Kaufman, et al.. (2020). Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 38(15_suppl). TPS8555–TPS8555. 3 indexed citations

14.

Aguirre, Luis E., et al.. (2019). Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience. Blood. 134(Supplement_1). 3131–3131. 18 indexed citations

15.

Elliott, Perry, Brian Drachman, Stephen S. Gottlieb, et al.. (2019). 1169Interim analysis of data from a long-term, extension trial of tafamidis meglumine in patients with transthyretin amyloid cardiomyopathy. European Heart Journal. 40(Supplement_1). 6 indexed citations

16.

Bradley, Terrence, Matthew Salzberg, Basem Azab, et al.. (2017). Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature. Blood. 130. 4885–4885. 1 indexed citations

17.

Apridonidze, Teimuraz, Richard M. Steingart, Raymond L. Comenzo, et al.. (2012). Clinical and Echocardiographic Correlates of Elevated Troponin in Amyloid Light-Chain Cardiac Amyloidosis. The American Journal of Cardiology. 110(8). 1180–1184. 17 indexed citations

18.

Zhou, Ping, James E. Hoffman, Heather Landau, et al.. (2011). Clonal Plasma Cell Pathophysiology and Clinical Features of Disease Are Linked to Clonal Plasma Cell Expression of Cyclin D1 in Systemic Light-Chain Amyloidosis. Clinical Lymphoma Myeloma & Leukemia. 12(1). 49–58. 24 indexed citations

19.

Zhou, Ping, Raymond L. Comenzo, Adam B. Olshen, et al.. (2008). CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody–based therapy. Blood. 111(7). 3403–3406. 35 indexed citations

20.

Tanenberg, Robert J., et al.. (1977). Lack of Glucagon Response to Hypoglycemia in Diabetic Autonomic Neuropathy. Diabetes. 26(3). 196–200. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact